Nevertheless, these novelfindings support the notion that lowering circulating Lp(a) levels would be asuitable therapeutic target to reduce residual CHD risk, and that LPAtargeting therapy could be a beneficial addition to statin treatment. This evidence concerns the gene LPA and coronary artery disorder.